AB133476

Anti-LRRK2 antibody [MJFF4 (c81-8)]

KO Validated
RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(9 Publications)

Rabbit Recombinant Monoclonal LRRK2 antibody. Suitable for WB, IP, IHC-P and reacts with Mouse, Human samples. Cited in 9 publications.

View Alternative Names

PARK8, LRRK2, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin

3 Images

Lab

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (AB133476)

Lane 1 : Wild-type HAP1 cell lysate (20 μg)
Lane 2 : LRRK2 knockout HAP1 cell lysate (20 μg)
Lane 3 : MEF cell lysate (20 μg)
Lane 4 : LRRK2 knockout MEF cell lysate (20 μg)
Lane 5 : A549 cell lysate (20ug)
Lane 6 : LRRK2 knockout A549 cell lysate (20 μg)

Lanes 1 - 6 : Merged signal (red and green). Green – ab133476 observed at 238 kDa. Red - loading control, ab130007, observed at 124 kDa.

ab133476 was shown to specifically react with LRRK2 in wild type A549, MEF and HAP1 cells along with additional cross-reactive bands. No band was observed when LRRK2 knockout samples were used. Wild-type and LRRK2 knockout samples were subjected to SDS-PAGE. ab133476 and ab130007 (loading control to Vinculin) were diluted at 1/500 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye^® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye^® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

Wild-type and LRRK2 knockout MEF and A549 cells were provide as a generous gift from Professor Dario Alessi, MRC Protein Phosphorylation and Ubiquitination Unit (University of Dundee).

All lanes:

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (ab133476)

Predicted band size: 286 kDa

false

Lab

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (AB133476)

ab133476 was shown to react with LRRK2 in wild-type A549 cells in Western blot with loss of signal observed in a LRRK2 knockout cell line. Wild-type A549 and LRRK2 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 5% milk in TBST for 1 hr before incubation with ab133476 overnight at 4 °C at a 1/500 dilution. Blots were incubated with secondary antibodies at 0.2 µg/mL before imaging.

These data were provided by YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins. Abcam and YCharOS are working together to help address the reproducibility crisis by enabling the life science community to better evaluate commercially available antibodies.

All lanes:

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (ab133476) at 1/500 dilution

Lane 1:

Wild-type A549 lysate at 25 µg

Lane 2:

LRRK2 knock-out A549 lysate at 25 µg

false

Supplier Data

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (AB133476)

All lanes:

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (ab133476) at 1/1000 dilution

Lane 1:

HEK293 cell lysate transfected with 3*Flag vector at 10 µg

Lane 2:

HEK293 cell lysate transfected with 3*Flag wild type Human LRRK2 full length at 10 µg

Secondary

All lanes:

HRP labelled goat anti-rabbit at 1/2000 dilution

Predicted band size: 286 kDa

false

This image is courtesy of Zhuohua Zhang Lab (Sanford-Burnham Medical Research Institute)

Carrier free

Anti-LRRK2 antibody [MJFF4 (c81-8)] - BSA and Azide free
Carrier free

Anti-LRRK2 antibody [MJFF4 (c81-8)] - Low endotoxin, Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

MJFF4 (c81-8)

Isotype

IgG

Carrier free

Reacts with

Mouse, Human

Applications

WB, IP, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

Product details

Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Abcam, has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community.

LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5′-diphosphate)/GTP (guanosine-5′-triphosphate) binding as well as GTP hydrolysis.

LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic.

For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750].

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein LRRK2 also known as leucine-rich repeat kinase 2 or dardarin is an enzyme with a molecular weight of approximately 286 kDa. It functions as a kinase meaning it adds phosphate groups to other proteins which affects their activity. LRRK2 is expressed in various tissues but it is highly abundant in the brain especially in regions such as the striatum and cortex. It has a significant role in cellular signaling processes due to its phosphorylation activity.

Biological function summary

LRRK2 interacts with cellular mechanisms by regulating cytoskeletal dynamics autophagy and vesicle trafficking. It is a part of a larger complex that includes other proteins involved in these processes. The kinase activity of LRRK2 plays an essential part in maintaining neuronal health and function. It influences the process of autophagy which is a way cells clean themselves by removing damaged components and recycling them.

Pathways

The action of LRRK2 is central to the mitogen-activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. In these pathways LRRK2 interacts with other proteins such as mTOR and RPS6KB1. It modulates cellular processes like growth proliferation and response to stressors. Its kinase activity affects the phosphorylation state of targets within the pathways hence influencing biological outcomes like survival and apoptosis.

LRRK2 mutations have a significant connection to Parkinson's disease and Crohn's disease. In Parkinson's disease mutated LRRK2 leads to abnormal protein aggregation linking to proteins such as alpha-synuclein. For Crohn's disease LRRK2 influences the immune response and intestinal inflammation. These connections highlight LRRK2's role in the pathogenesis and contribute to understanding these complex disorders.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

The protein expressed by the gene LRRK2 is a serine/threonine-protein kinase that phosphorylates a wide range of proteins involved in neuronal plasticity, autophagy, and vesicle trafficking. It serves as a key regulator of RAB GTPases by affecting the GTP/GDP exchange and interaction partners of RABs through phosphorylation, targeting proteins like RAB3A, RAB3B, and others. LRRK2 manages the GDP/GTP exchange for RAB8A by phosphorylating 'Thr-72', inhibiting RAB8A's interaction with GDI1/GDI2, and influencing primary ciliogenesis to enhance SHH signaling in the brain. It works with RAB29 in retromer-dependent recycling of proteins between lysosomes and the Golgi. The protein is involved in shaping neuronal morphology in the CNS, synaptic vesicle trafficking, and recruiting SEC16A to assist in ER to Golgi transport. It enhances autophagy via the CaMKK/AMPK pathway and relates to nicotinic acid adenine dinucleotide phosphate receptors and lysosomal activity. LRRK2 phosphorylates PRDX3 and APP, influencing neuron apoptosis. Independently, it inhibits MAPT degradation, fostering MAPT oligomerization. Additionally, LRRK2 possesses GTPase activity that regulates its kinase activity. This supplementary information is collated from multiple sources and compiled automatically.

See full target information LRRK2

style

left-column

Publications (9)

Recent publications for all applications. Explore the full list and refine your search

Investigative ophthalmology & visual science 61:45 PubMed32572455

2020

VIP Induces Changes in the F-/G-Actin Ratio of Schlemm's Canal Endothelium via LRRK2 Transcriptional Regulation.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoqin Yan,Mu Li,Zhaoxia Luo,Yin Zhao,Hong Zhang,Liwen Chen

Parkinsonism & related disorders 21:1156-63 PubMed26282470

2015

Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.

Applications

Unspecified application

Species

Unspecified reactive species

Mattia Volta,Stefano Cataldi,Dayne Beccano-Kelly,Lise Munsie,Igor Tatarnikov,Patrick Chou,Sabrina Bergeron,Emma Mitchell,Roscoe Lim,Jaskaran Khinda,Alejandro Lloret,C Frank Bennett,Carmela Paradiso,Michele Morari,Matthew J Farrer,Austen J Milnerwood

Human molecular genetics 24:1336-49 PubMed25343991

2014

LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.

Applications

Unspecified application

Species

Unspecified reactive species

Dayne A Beccano-Kelly,Mattia Volta,Lise N Munsie,Sarah A Paschall,Igor Tatarnikov,Kimberley Co,Patrick Chou,Li-Ping Cao,Sabrina Bergeron,Emma Mitchell,Heather Han,Heather L Melrose,Lucia Tapia,Lynn A Raymond,Matthew J Farrer,Austen J Milnerwood

Neurobiology of disease 71:345-58 PubMed25174890

2014

Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.

Applications

Species

Mouse

Elpida Tsika,Meghna Kannan,Caroline Shi-Yan Foo,Dustin Dikeman,Liliane Glauser,Sandra Gellhaar,Dagmar Galter,Graham W Knott,Ted M Dawson,Valina L Dawson,Darren J Moore

Cell death & disease 5:e1217 PubMed24810053

2014

Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model.

Applications

Species

Rat

S Yang,C Xia,S Li,L Du,L Zhang,Y Hu

Human molecular genetics 23:2055-77 PubMed24282027

2013

Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.

Applications

Unspecified application

Species

Mouse

Klodjan Stafa,Elpida Tsika,Roger Moser,Alessandra Musso,Liliane Glauser,Amy Jones,Saskia Biskup,Yulan Xiong,Rina Bandopadhyay,Valina L Dawson,Ted M Dawson,Darren J Moore

The Biochemical journal 453:101-13 PubMed23560750

2013

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.

Applications

WB, IP, IP, IP, WB, WB

Species

Mouse, Human, Rat, Mouse, Rat, Human

Paul Davies,Kelly M Hinkle,Nour N Sukar,Bryan Sepulveda,Roxana Mesias,Geidy Serrano,Dario R Alessi,Thomas G Beach,Deanna L Benson,Charles L White,Rita M Cowell,Sonal S Das,Andrew B West,Heather L Melrose

PloS one 7:e47784 PubMed23082216

2012

Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.

Applications

WB, WB

Species

Mouse, Human

Alzbeta Trancikova,Adamantios Mamais,Philip J Webber,Klodjan Stafa,Elpida Tsika,Liliane Glauser,Andrew B West,Rina Bandopadhyay,Darren J Moore

PloS one 6:e18568 PubMed21494637

2011

Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

Applications

Species

Mouse

David Ramonet,João Paulo L Daher,Brian M Lin,Klodjan Stafa,Jaekwang Kim,Rebecca Banerjee,Marie Westerlund,Olga Pletnikova,Liliane Glauser,Lichuan Yang,Ying Liu,Deborah A Swing,M Flint Beal,Juan C Troncoso,J Michael McCaffery,Nancy A Jenkins,Neal G Copeland,Dagmar Galter,Bobby Thomas,Michael K Lee,Ted M Dawson,Valina L Dawson,Darren J Moore

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-LRRK2 antibody [MJFF4 (c81-8)]

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (AB133476)

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (AB133476)

Western blot - Anti-LRRK2 antibody [MJFF4 (c81-8)] (AB133476)

Related conjugates and formulations (2)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (9)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Product promise